Plain-English translation of NCT06814730 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new medication called to see if it is safe and how the body handles it in people with early Alzheimer's disease and a condition affecting small blood vessels in the brain. Researchers will give some participants the medication and others a placebo (a dummy treatment) as monthly IV infusions over several months. The study will carefully monitor participants' safety, brain health, and how the medication moves through the body.
Early Alzheimer's disease combined with small vessel disease can be especially challenging, and current treatments have limited options. This trial is exploring whether this new medication might be a safe and effective option for slowing memory decline in this population.
If you enroll, you will visit the clinic monthly for 3–6 IV infusions of either the medication or a placebo, with follow-up visits continuing for 6 months after your last dose. During these visits, you'll have brain imaging (MRI scans), occasional spinal taps, heart monitoring, blood tests, and cognitive assessments to track your memory and thinking. The entire commitment will be 8–11 months, depending on which treatment group you're assigned to.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
Netherlands
United Kingdom